Voyager Therapeutics, Inc.
VYGR
$3.17
-$0.26-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.02M | -34.49M | -9.04M | -10.14M | -11.33M |
| Total Depreciation and Amortization | 1.01M | 1.01M | 1.13M | 1.39M | 1.20M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.93M | 2.26M | 1.56M | 4.58M | 2.76M |
| Change in Net Operating Assets | -11.81M | 16.69M | -21.62M | -27.41M | 66.14M |
| Cash from Operations | -37.90M | -14.53M | -27.97M | -31.58M | 58.77M |
| Capital Expenditure | -658.00K | -155.00K | -258.00K | -967.00K | -2.14M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.86M | -27.05M | 64.61M | -34.98M | -93.92M |
| Cash from Investing | 41.20M | -27.20M | 64.35M | -35.94M | -96.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 82.00K | 574.00K | 14.00K | 571.00K | 112.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 82.00K | 574.00K | 14.00K | 571.00K | 112.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.39M | -41.16M | 36.40M | -66.95M | 75.56M |